Date: 2011-10-25
Type of information: Production agreement
Compound: HuMax-TF®
Company: Lonza (Switzerland) Genmab (Denmark)
Therapeutic area: Cancer Oncology
Type agreement: development
manufacturing
production
Action mechanism:
Disease: \
Details: Lonza and Genmab have concluded a new development and manufacturing agreement.This agreement secures a development and cGMP manufacturing plan for Genmab to produce a novel ADC product targeting tissue factor (TF), a protein involved in tumor signalling and angiogenesis that is highly expressed on solid tumors. This project utilizes Lonza’s experts in both antibody production and drug conjugation, providing a harmonized solution for Genmab’s technology. Lonza will initiate process development and cGMP manufacturing for Genmab’s monoclonal antibody HuMax-TF™ in its Slough, UK facility. This antibody has been expressed by Genmab A/S in Lonza’s GS Gene Expression System™. The naked antibody will be conjugated by Lonza at its ADC plant in Visp, CH to a cytotoxic drug in order to form the antibody drug conjugate HuMax-TF™.
Financial terms: Financial details of the agreement were not disclosed
Latest news:
